Catching Cancer Earlier, One Breath at a Time: SpotitEarly Partners with HITLAB to Accelerate Its U.S. Launch
The strategic collaboration connects HITLAB’s healthcare investor network and health-system relationships with SpotitEarly as the company prepares for U.S. commercialization of its Bio-AI Hybrid breath test
When breast cancer is caught while it is still confined to the breast, the five-year relative survival rate is about 99%. Once it has spread to distant parts of the body, that figure falls to roughly 31%, according to the National Cancer Institute. SpotitEarly is working to move far more patients into that first group with a screening test as simple as breathing into a mask. Today, the multi-cancer early-detection company announced a strategic partnership with HITLAB (Healthcare Innovation and Technology Lab), a globally recognized health-technology research and innovation organization based in New York City, to accelerate its U.S. commercialization and capital development.
SpotitEarly’s platform does something no conventional screening test does: it reads the odor signature of cancer in a person’s breath. Its LUCID Bio-AI Hybrid system combines machine learning with the scent-detection abilities of trained canines, using sensors to capture and standardize the dogs’ behavioral and physiological responses into consistent, data-driven results. In the peer-reviewed, double-blind Rainbow Study, published in Scientific Reports, the platform achieved 93.9% sensitivity and 94.3% specificity.
